CareDx, Inc.
$70.00-$1.92 (-2.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.2B
- P/E
- -55.9x
- EV / EBITDA
- -248.1x
- Revenue
- $379.8M
- Net margin
- -5.6%
- ROCE
- -7.8%
Price chart
Technical chartScreen technicals →+344.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +1.2%
- 3M
- +49.0%
- 6M
- +231.0%
- 1Y
- +344.2%
- 5Y
- +62.8%
52-week range
Day change -$1.92 (-2.7%) from $72 to $70 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in CDNA, bought on each weekday since 2021.
News & filings
What CareDx filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 21.4 million US dollars in fiscal 2025.
Strengths (1)
- The price is 84.0% above its 200-day average, and the 50-day average is above the 200-day.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
Read moreShow less
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Shares outstanding
- 50.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.2B
- P/E
- -55.9x
- P/B
- 3.9x
- EV / EBITDA
- -248.1x
- EV / Sales
- 3.0x
- P/S
- 3.1x
- 52-week high
- $88.47
- 52-week low
- $15.76
Profitability
- Operating margin
- -6.6%
- Net margin
- -5.6%
- EBITDA margin
- -1.2%
- ROE
- -7.0%
- ROCE
- -7.8%
- ROIC
- -7.5%
- ROA
- -5.2%
- Asset turnover
- 0.92
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $379.8M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 13.8%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 5.7%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -140.6%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $35.4M
Solvency
- Current ratio
- 2.86
- Debt / Equity
- 0.09
- Debt / Assets
- 0.06
- CFO / Net profit
- -1.97
- Cash / Market cap
- 5.5%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $379.8M |
| Cost of revenue | $123.2M |
| Gross profit | $256.6M |
| Operating expenses | $281.6M |
| Research and development | $71.4M |
| Selling, general and administrative | $210.2M |
| Operating income | -$25.1M |
| Interest and other | $4.0M |
| Pretax income | -$21.1M |
| Tax and other | $270.0k |
| Net income | -$21.4M |
Revenue and net profit
Revenue grew 13.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $321.8M | -$76.6M |
| FY2023 | $280.3M | -$190.3M |
| FY2024 | $333.8M | $52.5M |
| FY2025 | $379.8M | -$21.4M |
Cash flows
FY2025: $42.0M from operations, $35.4M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$25.2M | -$49.6M |
| FY2023 | -$18.4M | -$27.6M |
| FY2024 | $38.0M | $31.6M |
| FY2025 | $42.0M | $35.4M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $379.8M+13.8%1Y
- EBITDA
- -$4.7M
- Net profit
- -$21.4M-140.6%1Y
- Cash from operations
- $42.0M+10.5%1Y
- Free cash flow
- $35.4M+12.3%1Y
- Revenue CAGR, 3Y
- 5.7%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $379.8M | -$4.7M | -$21.4M | $35.4M | -7.0% | +13.8% | -140.6% |
Monthly returns
Month-by-month returns of CDNA across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $413.2M |
| Current assets | $257.1M |
| Non-current assets | $156.1M |
| Liabilities | $110.1M |
| Current liabilities | $89.8M |
| Non-current liabilities | $20.3M |
| Equity | $303.1M |
| Paid-in capital | $1.0B |
| Retained earnings | -$735.4M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; CDNA highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| CareDx, Inc.CDNAthis company | $1.2B | -55.9x | 3.9x | -7.0% | -248.1x |
| Alphatec Holdings, Inc.ATEC | $1.2B | — | 98.1x | -1154.3% | — |
| Inspire Medical Systems, Inc.INSP | $1.2B | 8.4x | 1.6x | 18.6% | 14.3x |
| IRADIMED CORPORATIONIRMD | $1.2B | 53.2x | 12.6x | 23.8% | 41.9x |
| Kestra Medical Technologies, Ltd.KMTS | $1.2B | -10.5x | 5.8x | -55.4% | -10.2x |
| AMN Healthcare Services, Inc.AMN | $1.2B | — | 1.8x | -14.9% | 19.3x |
| Schrödinger, Inc.SDGR | $1.2B | -11.5x | 3.3x | -28.4% | -6.6x |
| Wave Life Sciences Ltd.WVE | $1.2B | — | 2.3x | -39.4% | — |
| Avanos Medical, Inc.AVNS | $1.2B | — | 1.5x | -9.4% | — |
| Peer median | — | -1.1x | 2.8x | -21.6% | 14.3x |
Year-to-date ROI
CDNA since 1 January, against earlier years.
Historical volatility
CDNA's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -24.0% |
| FY2023 | -38.2% |
| FY2024 | -16.6% |
| FY2025 | -6.6% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $379.8M |
| Cost of revenueCost Of Revenue | $123.2M |
| Gross profitGross Profit | $256.6M |
| Operating expensesOperating Expense | $281.6M |
| Research and developmentResearch And Development | $71.4M |
| Selling, general and administrativeSelling General And Administration | $210.2M |
| Total expensesTotal Expenses | $404.9M |
| Operating incomeOperating Income | -$25.1M |
| Interest and other | |
| Pretax incomePretax Income | -$21.1M |
| TaxTax Provision | $270.0k |
| Net incomeNet Income | -$21.4M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $413.2M |
| Current assetsCurrent Assets | $257.1M |
| Non-current assetsTotal Non Current Assets | $156.1M |
| LiabilitiesTotal Liabilities Net Minority Interest | $110.1M |
| Current liabilitiesCurrent Liabilities | $89.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $20.3M |
| EquityTotal Equity Gross Minority Interest | $303.1M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $42.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $42.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$21.4M |
| Depreciation and amortisationDepreciation And Amortization | $20.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $20.4M |
| Depreciation | $20.4M |
| Amortization of securitiesAmortization Of Securities | $1.3M |
| Stock-based compensationStock Based Compensation | $34.9M |
| Deferred taxDeferred Tax | $20.0k |
| Deferred income taxDeferred Income Tax | $20.0k |
| Operating gains and lossesOperating Gains Losses | $50.0k |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | — |
| Asset impairmentAsset Impairment Charge | $2.3M |
| Change in working capitalChange In Working Capital | $3.8M |
| Other non-cash itemsOther Non Cash Items | $700.0k |
| Investing cash flowInvesting Cash Flow | $2.2M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $2.2M |
| Capital expenditureCapital Expenditure | -$6.6M |
| Capital expenditure (reported)Capital Expenditure Reported | -$5.9M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$145.9M |
| Sale of investmentsSale Of Investment | $154.7M |
| Net investment purchases and salesNet Investment Purchase And Sale | $8.8M |
| Purchase of intangiblesPurchase Of Intangibles | -$680.0k |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$680.0k |
| Financing cash flowFinancing Cash Flow | -$93.4M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$93.4M |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | — |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | — |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$87.8M |
| Common stock repurchasedCommon Stock Payments | -$87.8M |
| Share buybacksRepurchase Of Capital Stock | -$87.8M |
| Stock options exercisedProceeds From Stock Option Exercised | $8.0M |
| Other financing chargesNet Other Financing Charges | -$13.6M |
| Change in cashChanges In Cash | -$49.2M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | -9.0% |
| Cash at the start of the yearBeginning Cash Position | $115.3M |
| Cash at the end of the yearEnd Cash Position | $66.0M |
| Free cash flowFree Cash Flow | $35.4M |
| Supplemental |
Learn while you research
Academy chapters picked for CareDx, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read